Related Experiment Video
Updated: Jul 31, 2026
08:13
Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test (OGTT) and Insulin Tolerance Test (ITT)
Published on: January 7, 2018
European Union diabetes indicators: fact or fiction?
C E de Beaufort1, A Reunanen, V Raleigh
1Clinique Pediatrique Luxemburg, GD de Luxemburg. debeaufort.carine@chl.lu
European Journal of Public Health
|October 10, 2003
Summary
Monitoring diabetes mellitus in EU/EFTA countries requires standardized indicators and data sources. This study proposes core and secondary indicators to track risk factors and complications, aiming for better comparability and intervention evaluation.
Area of Science:
- Public Health
- Epidemiology
- Health Services Research
Background:
- Diabetes mellitus is a leading cause of illness and death in EU/EFTA nations.
- Effective monitoring of diabetes risk factors and complications is crucial for evaluating disease progression and intervention effectiveness.
Purpose of the Study:
- To propose a list of core and secondary indicators for monitoring diabetes mellitus.
- To discuss the availability and sources of these proposed indicators within EU/EFTA countries.
- To identify challenges in data comparability and suggest improvements for routine monitoring.
Main Methods:
- Literature review and expert consultation to identify relevant diabetes indicators.
- Analysis of existing data sources used for diabetes monitoring in EU/EFTA countries.
- Assessment of data variability and comparability across different countries.
Main Results:
- A proposed list of core and secondary indicators for diabetes monitoring.
- Identification of diverse and variable data sources across EU/EFTA countries.
- Significant challenges in data comparability due to differing sources and methodologies.
Conclusions:
- Harmonization of data sources is essential for reliable diabetes monitoring in the EU/EFTA region.
- Continuous evaluation of data sources is necessary to ensure the validity of monitoring tools.
- Standardized monitoring will facilitate better assessment of interventions and outcomes for diabetes mellitus.
Related Concept Videos
01:22Diabetes Mellitus: Overview and Type I Subtype
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
01:22Diabetes Mellitus: Type 2 and Gestational
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
01:15Diabetes: Symptoms, Diagnosis, and Complications
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is based on...
01:15Diabetes: Management and Pharmacotherapy
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
01:19Type I Diabetes III: Clinical Manifestations
Type 1 diabetes mellitus typically presents with rapid-onset symptoms due to the body’s inability to utilize glucose in the absence of insulin. Since insulin is required for glucose uptake into cells, its deficiency leads to hyperglycemia and cellular energy deprivation, resulting in characteristic clinical features.Polyuria and PolydipsiaOne of the earliest, most prominent symptoms is polyuria (excessive urination). When blood glucose concentrations rise above the renal threshold, the kidneys...
01:25Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis
Type 2 diabetes mellitus develops gradually and is often asymptomatic in early stages.Clinical ManifestationsWhen symptoms appear, they include fatigue, blurred vision, pruritus, delayed wound healing, and recurrent infections, particularly candidal infections. Peripheral neuropathy may present as numbness or tingling in the extremities. Classic hyperglycemia symptoms—polyuria, polydipsia, and polyphagia—are less common. Most patients are overweight and frequently have associated hypertension...